SCHEMBL6563172

SCHEMBL6563172

O=CN(CCCc1ccc(CCNC(=O)OCc2ccccc2)cc1)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TGM2 P21980 1/20 0.48
KEAP1 Q14145 2/20 0.45
NFE2L2 Q16236 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6561783 0.95 HTT (0.53) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL4827129 0.87 TGM2 (0.60) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL6253004 0.83 KCNH2 (0.43)
SCHEMBL6561674 0.82 SMN1; SMN2 (0.47) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL6563145 0.81 LMNA (0.46) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL6561744 0.81 LMNA (0.44) HTTLMNASMN1; SMN2TGM2KEAP1
Benzyl Phenethylcarbamate SCHEMBL4287199 0.80 LMNA (0.73) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL6748819 0.79 HTT (0.72) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL26665217 0.78 LMNA (0.58) HTTLMNASMN1; SMN2TGM2KEAP1
SCHEMBL6554125 0.77 LMNA (0.65) HTTLMNASMN1; SMN2TGM2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 HTT 498/4885LMNA 4815/4885SMN1; SMN2 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.